Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
333,994 | 336,006 | 418,305 | 438,737 | 563,340 |
Cost of Goods Sold (COGS) incl. D&A |
87,715 | 38,536 | 114,423 | 39,211 | 30,127 |
COGS excluding D&A |
75,342 | 29,943 | 105,758 | 30,651 | 20,403 |
Depreciation & Amortization Expense |
12,373 | 8,593 | 8,665 | 8,560 | 9,724 |
Gross Income |
246,279 | 297,470 | 303,882 | 399,526 | 533,213 |
SG&A Expense |
323,561 | 297,845 | 314,058 | 307,517 | 308,319 |
Research & Development |
213,109 | 200,161 | 196,544 | 196,371 | 186,438 |
Other SG&A |
110,452 | 97,684 | 117,514 | 111,146 | 121,881 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
194 | 696 | 594 | 360 | 1,860 |
Non Operating Income/Expense |
0 | 0 | 0 | 0 | 197 |
Equity in Affiliates (Pretax) |
NA | 0 | 0 | 0 | 0 |
Interest Expense |
3,793 | 4,560 | 4,195 | 4,105 | 12,430 |
Gross Interest Expense |
3,793 | 4,560 | 4,195 | 4,105 | 12,430 |
Pretax Income |
-80,772 | -5,112 | -14,405 | 87,908 | 210,801 |
Income Tax |
-2,696 | 21,355 | 20,063 | 32 | 22,660 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
-78,076 | -26,467 | -34,468 | 86,970 | 188,141 |
Minority Interest Expense |
-1,928 | 31,076 | 30,463 | -3,714 | 29,512 |
Net Income |
-76,148 | -57,543 | -64,931 | 90,684 | 158,629 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | NA | 0 |
Net Income After Extraordinaries |
-76,148 | -57,543 | -64,931 | 90,684 | 158,628 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
-76,148 | -57,543 | -64,931 | 90,684 | 158,629 |
Operational EPS |
-0.35 | -0.27 | -0.31 | 0.43 | 0.73 |
EPS (basic) |
-0.35 | -0.27 | -0.31 | 0.44 | 0.77 |
EBITDA |
-64,909 | 8,218 | -1,511 | 100,569 | 234,618 |
Depreciation & Amortization Expense |
12,373 | 8,593 | 8,665 | 8,560 | 9,724 |
Common Shares Outstanding |
214,607 | 213,767 | 211,344 | 219,264 | 217,602 |
Basic Shares Outstanding |
214,607 | 213,767 | 211,344 | 208,018 | 206,758 |
Diluted Shares Outstanding |
214,607 | 213,767 | 211,344 | 219,264 | 217,602 |
Diluted EPS after Extraordinary Items |
-0.35 | -0.27 | -0.31 | 0.43 | 0.73 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
-0.35 | -0.27 | -0.31 | 0.44 | 0.76 |
*Figures in thousands of U.S. Dollars except shares outstanding.
